A 1211212

Drug Profile

A 1211212

Alternative Names: A-1211212

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 06 May 2017 Preclinical trials in Inflammatory bowel disease in USA (PO)
  • 06 May 2017 Pharmacodynamics data from a preclinical study in Inflammatory bowel disease presented at the Digestive Disease Week (DDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top